Patents Examined by My-Chau T Tran
  • Patent number: 10610592
    Abstract: A composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. A method of treating neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and treating neurodegeneration. A method of reducing and/or eliminating symptoms of neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and reducing and/or eliminating the individual's symptoms of neurodegeneration. A method of reducing and/or eliminating lesions from neurodegeneration. A method of recovering mobility of an individual suffering from neurodegeneration.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 7, 2020
    Inventor: Fabrizio De Silvestri
  • Patent number: 10610508
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 7, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Patent number: 10583145
    Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 10, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thomas J. Slaga, Jacob Junco, Huiyun Liang, Sara Reyna
  • Patent number: 10568852
    Abstract: The present invention relates to compositions comprising at least two different active compounds and the use of such combination compositions in medicine, in particular in methods for treating obesity and obesity-related disorders and/or in methods for inhibiting weight gain.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 25, 2020
    Assignee: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Timo Dirk Mueller, Matthias Tschoep, Christoffer Clemmensen, Brian Finan
  • Patent number: 10568869
    Abstract: The invention is directed to a method of inhibiting prostate cancer cell proliferation using a substance that inhibits the activity of a soluble adenylyl cyclase (sAC) protein. The invention also is directed to methods of diagnosing and prognosticating prostate cancer in a subject by evaluating sAC gene or protein expression in the subject.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: February 25, 2020
    Assignee: CORNELL UNIVERSITY
    Inventors: Brian Robinson, Jonathan Zippin
  • Patent number: 10555903
    Abstract: The present disclosure relates to a nebulization composition comprising tiotropium and formoterol for the treatment of inflammatory or obstructive airway disease. The present disclosure also relates to a process for preparing the composition.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 11, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ramprasad Murugan, Mahadeorao S. Rase, Franciscus Koppenhagen, Julianne Berry
  • Patent number: 10525028
    Abstract: [Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 7, 2020
    Assignee: NIPPON SUISAN KAISHA, LTD.
    Inventors: Jiro Takeo, Hiroyuki Kawahara
  • Patent number: 10517850
    Abstract: The present invention provides a pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a particular TAFIa inhibitor and a plasminogen activator, the TAFIa inhibitor being administered in combination with the plasminogen activator, and a method for treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a particular TAFIa inhibitor in combination with a plasminogen activator to a warm-blooded animal.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: December 31, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kengo Noguchi, Yusuke Ito, Naoko Edo
  • Patent number: 10512641
    Abstract: Described herein are methods for treating cancer in a subject in need thereof by administering chloroquine, or a salt or prodrug thereof, optionally with another agent that promotes Par-4 production to induce prostate apoptosis response-4 (Par-4) production by host cells, particularly non-cancerous host cells, to promote apoptosis in cancer cells, including androgen insensitive prostate cancer cells.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 24, 2019
    Assignee: University of Kentucky Research Foundation
    Inventor: Vivek M. Rangnekar
  • Patent number: 10493045
    Abstract: A method for treating alcohol dependence or alcohol abuse in a subject comprising administering to the subject a composition comprising an effective amount of memantine, wherein the effective amount of memantine is 2-4.7 mg/day. Low dose of memantine having anti-inflammatory and neurotrophic effect is able to reduce alcohol use.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 3, 2019
    Inventor: Ru-Band Lu
  • Patent number: 10485793
    Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 26, 2019
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventor: William J. Polvino
  • Patent number: 10472315
    Abstract: The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using various naphthoquinone, hydroxyquinonline, and naphthothiazole compounds.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: November 12, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jun O. Liu, Omonike Arike Olaleye, Shridhar Bhat
  • Patent number: 10463668
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: November 5, 2019
    Assignee: Pharmacyclics LLC
    Inventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
  • Patent number: 10456472
    Abstract: The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: October 29, 2019
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: David Gschneidner, Stephen V. Pusztay
  • Patent number: 10449190
    Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 22, 2019
    Inventor: John K. Thottathil
  • Patent number: 10449146
    Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: October 22, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Scott David Barnhart, Michael Clinton Koons, Madhu Sudan Hariharan, Jordan Dubow, Thierry Bilbault, Anthony John Giovinazzo
  • Patent number: 10442773
    Abstract: The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30° C. to 60° C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: October 15, 2019
    Assignee: AICURIS ANTI-INFECTIVE CURES GMBH
    Inventors: Wilfried Schwab, Dirk Jung, Christian Schickaneder, Welljanne Martens, Michael Limmert, Clemens Bothe, Mathias Berwe, Nicole Rindermann
  • Patent number: 10434112
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 8, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • Patent number: 10434104
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: October 8, 2019
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Patent number: 10420838
    Abstract: Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human melanoma, or a head or neck cancer, that employ therapeutically-effective amounts of one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents (including, for example, calcium channel antagonists), alone, or further in combination with one or more conventional chemotherapeutic agents. Also disclosed are pharmaceutical formulations that comprise these compositions, as well as methods for their use in treating refractory, metastatic, and/or relapsed cancers, or, for use in the management or reversal of treatment resistance in one or more such mammalian cancers.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: September 24, 2019
    Assignee: The Methodist Hospital
    Inventor: Jenny Chee Ning Chang